Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

A researcher in a lab coat working with a microscope, studying a biopharmaceutical drug. Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug ...

But the headline is that CagriSema allowed people to lose 20.4% of their body weight on average—better than Wegovy, but about on par with what people can achieve with Eli Lilly’s Zepbound.

Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial ... However, this is far from the case. I'm going to break down why a recent piece of ...

The OnePlus 13 has now been announced for the U.S., and if you've bought one, you'll want to keep it safe with one of the ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...